Clinical Case Database / Category: Patient Management

Mechanism of action, monitoring & reversal of neuromuscular blocking agents: the use of Sugammadex

Publication details

Dr T Jacobs, MV Copp
Foundation Years Journal, volume 9, issue 8, p.45 (123Doc Education, London, September 2015)

Abstract

The classical triad of anaesthesia consists of hypnosis, analgesia and muscle relaxation. The introduction of neuromuscular blocking drugs (NMB) in the 1940's transformed the way in which anaesthesia could be safely delivered to patients. The NMB drugs provided the ability to paralyze patients to facilitate intubation of the trachea and provide muscle relaxation during major surgery. The NMB drugs work by occupying nicotinic Acetylcholine receptors (nAchR) in a competitive antagonism with endogenous acetylcholine (Ach) at the neuromuscular junction. At the end of surgery muscle paralysis usually needs to be reversed by the administration of anticholinesterase drugs such as Neostigmine. These drugs have known side effects which can give rise to problems in some patients. A new novel drug called Sugammadex has been introduced into anaesthetic clinical practice which has a completely different mechanism of action to reverse NMB drugs. It brings significant safety benefits for some patients. Its drawback is that it is expensive. In this article we will overview the role and mechanism of action of NMB drugs, including reversal, and will highlight some specific indications for Sugammadex.

Access the Clinical Cases Database

A subscription is required to read the full article. Please subscribe using one of the options below.

ProductPriceSubscription
Foundation Years Clinical Cases Database£29.006 months
Add to cart
Foundation Years Clinical Cases Database£39.0012 months
Add to cart

Authors

Dr T Jacobs (Corresponding author)

ST5 in Anaesthesia Severn Deanery
Department of Anaesthesia
Cheltenham General Hospital
Cheltenham, GL52 3BS
tobyjacobs@doctors.net.uk

MV Copp

Consultant Anaesthetist
Gloucestershire Hospitals NHSFT
Department of Anaesthesia
Cheltenham General Hospital
Cheltenham, GL52 3BS
michael.copp@glos.nhs.uk

References

1. Jonas Appiah-Ankam and Jennifer M Hunter. Pharmacology of neuromuscular blocking drugs. Contin Educ Anaesth Crit Care Pain (2004) 4 (1): 2-7
2. Ali HH, Utting JE, Gray TC. Stimulus frequency in the detection of neuromuscular block in humans. Brit. J. Anaesth. 1970; 42: 967–78
3. M. Naguib, A.F.Kopman, J.E.Ensor. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br. J. Anaesth. (2007) 98 (3): 302-316
4. Murphy, Glenn S.; Brull, Sorin J. Residual Neuromuscular Block: Lessons Unlearned. Part I: Definitions, Incidence, and Adverse Physiologic Effects of Residual Neuromuscular Block. Anesthesia & Analgesia. July (2010) 111 (1):120-128
5. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009; 24: 29-35.
6. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth. 2014; 112: 498-505.
7. Lee C, Jahr JS, CandiottKA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium. Anesthesiology. 2009; 110:1020-5

Disclaimers

Conflict Of Interest

The Journal requires that authors disclose any potential conflict of interest that they may have. This is clearly stated in the Journal’s published “Guidelines for Authors”. The Journal follows the Guidelines against Conflict of Interest published in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/urm_full.pdf).

Financial Statement

The authors of this article have not been paid. The Journal is financed by subscriptions and advertising. The Journal does not receive money from any other sources. The decision to accept or refuse this article for publication was free from financial considerations and was solely the responsibility of the Editorial Panel and Editor-in-Chief.

Patient Consent statement

All pictures and investigations shown in this article are shown with the patients’ consent. We require Authors to maintain patients’ anonymity and to obtain consent to report investigations and pictures involving human subjects when anonymity may be compromised. The Journal follows the Guidelines of the Uniform Requirements for Manuscripts (http://www.icmje.org/urm_full.pdf). The Journal requires in its Guidelines for Authors a statement from Authors that “the subject gave informed consent”.

Animal & Human Rights

When reporting experiments on human subjects, the Journal requires authors to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the HelsinkiDeclaration of 1975, as revised in 2008.

About the Clinical Cases Database

T​he Foundation Years Clinical Cases Database is​ a selection of 600 peer-reviewed clinical cases in the field of patient safety and clinical practice, specifically focused on the clinical information needs of junior doctors, based around the Foundation Year Curriculum programme (MMC). The cases have been chosen to align with the Foundation Year Curriculum.

The database is fully searchable, or can be browsed by medical specialty. Abstracts can be read free of charge, however a subscription is required in order to read the complete cases.